Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation
Overview
Authors
Affiliations
Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1 by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases. Understanding the contribution of the enzyme activity-independent and enzyme activity-dependent functions, which often appear to be mediated by the hydrogen peroxide production, in the VAP-1 biology will be crucial. Similarly, there is a pressing need to understand which of the VAP-1 functions are regulated through the modulation of leukocyte trafficking, and what is the role of VAP-1 synthesized in adipose and smooth muscle cells. The specificity and selectivity of new VAP-1 inhibitors, and their value in animal models under therapeutic settings need to be addressed. Results from several programs studying the therapeutic potential of VAP-1 inhibition, which now are in clinical trials, will reveal the relevance of this amine oxidase in humans.
Case report: Detecting giant cell arteritis in [Ga]Ga-DOTA-Siglec-9-PET/CT.
Petzinna S, Kuppers J, Schemmer B, Kernder A, Bauer C, von der Emde L Front Immunol. 2025; 15:1501790.
PMID: 39763674 PMC: 11701584. DOI: 10.3389/fimmu.2024.1501790.
Gong S, Huang R, Wang M, Lian F, Wang Q, Liao Z J Transl Med. 2024; 22(1):1016.
PMID: 39529035 PMC: 11552364. DOI: 10.1186/s12967-024-05843-y.
Vascular-adhesion protein 1 in giant cell arteritis and polymyalgia rheumatica.
Petzinna S, Bauer C, Schafer V Front Med (Lausanne). 2024; 11:1448157.
PMID: 39206172 PMC: 11349539. DOI: 10.3389/fmed.2024.1448157.
Ozcan O, Akyol O, Akyol A In Vivo. 2024; 38(5):2300-2309.
PMID: 39187313 PMC: 11363779. DOI: 10.21873/invivo.13695.
Cebi M, Yilmaz Y Front Immunol. 2024; 15:1445634.
PMID: 39148730 PMC: 11324455. DOI: 10.3389/fimmu.2024.1445634.